Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 20 | ECE2009 | Next issue

11th European Congress of Endocrinology

Debate

What to do next when Metformin does not work in Type 2 Diabetes?

ea0020d1.1 | What to do next when Metformin does not work in Type 2 Diabetes? | ECE2009

What to do next when metformin does not work in diabetes Type2? add SU

Pirags Valdis

Monotherapy with metformin is widely accepted as the second step in type 2 diabetes treatment after the failure to achieve glycemic goals with therapeutic education and lifestyle modification, including correction of diet and physical exercise habits. However, most of patients need combination therapy in first three to four years after metformin initiation. Obviously the efficacy of antidiabetic drugs used as add-on to metformin monotherapy could be different from those observ...

ea0020d1.2 | What to do next when Metformin does not work in Type 2 Diabetes? | ECE2009

Add insulin

Battelino Tadej

People with type 2 Diabetes (T2D) develop severe chronic complication early in the course of the disease if not treated optimally. Although lifestyle intervention and metformin clearly improve metabolic control with metformin having well established safety profile, both become insufficient in most patients with T2D. To achieve the current goal of HbA1c < 7% additional medication are introduced.By current recommendations, basal insulin or sulfonylurea...

ea0020d1.3 | What to do next when Metformin does not work in Type 2 Diabetes? | ECE2009

What to do next when metformin does not work in diabetes Type 2? add incretin

Gallwitz Baptist

Near-normoglycaemia shold be reached as safely as possible. It should be considered, that at lower HbA1c concentrations, the proportional contribution of postprandial glucose to HbA1c is greater than at higher HbA1c values.Sulfonylureas, glinides and insulin are associated with an increased risk for hypoglycaemia and weight gain. Therefore, these agents should not be considered in first line for the combination therapy in overweight patients with Type 2 ...